Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CytomX Therapeutics, Inc. (CTMX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - CX-904 initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 and CX-801 anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., August 8, 2023 –"
05/09/2023 8-K Quarterly results
Docs: "CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Continued progress in Phase 1 dose escalation for CX-904 - - IND enabling activities on track for filings for CX-2051 and CX-801 in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1 to Phase 2 clinical evaluation as lead, next-generation CTLA-4 program - - CD71strategy under evaluation including potential further advancement of CX-2029 and next generation CD71 targeting strategies - - Continued progress in strategic alliances including a $5 million clinical candidate milestone in Probody® T-Cell Bispecific collaboration with Astellas and initiation of Regeneron and Moderna collaborations - - Marcia Belvin, Ph.D. promoted to C..."
03/27/2023 8-K Quarterly results
11/08/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab ravtansine expected in 2022- SOUTH SAN FRANCISCO, Calif., November 4, 2021 –"
05/06/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "- Q3-20 EARNINGS RELEASE"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Exhibit 99.1 CytomX Therapeutics Announces Third Quarter 2019 Financial Results -Company to Host a Conference Call Today, November 7, 2019, at 5:00 p.m. ET / 2:00 p.m. PT-"
08/07/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "CytomX Therapeutics Investors: Christopher Keenan VP, Investor Relations and Corporate Communications [email protected]"
11/06/2018 8-K Quarterly results
Docs: "Press release titled “CytomX Therapeutics Announces Third Quarter 2018 Financial Results” issued by CytomX Therapeutics, Inc. on November 6, 2018"
05/09/2018 8-K Quarterly results
Docs: "CytomX Therapeutics Announces First Quarter 2018 Financial Results - Initial clinical data from the Phase 1/2 CX-072 program to be reported at American Society of Clinical Oncology Annual Meeting -"
11/07/2017 8-K Quarterly results
Docs: "CytomX Announces Third Quarter 2017 Financial Results and Operational Progress"
08/07/2017 8-K Quarterly results
Docs: "CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call Strong Pipeline Momentum Continues Initiated Combination Arms in Phase 1/2 PROCLAIM-CX-072 Study Initiated Phase 1/2 PROCLAIM-CX-2009 Study"
05/05/2017 8-K Form 8-K - Current report
03/02/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
05/06/2016 8-K Form 8-K - Current report
03/07/2016 8-K Form 8-K - Current report
11/23/2015 8-K Quarterly results
Docs: "–"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy